Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor.
Anaplastic Lymphoma Kinase
/ genetics
Animals
Biomarkers, Tumor
/ genetics
Carcinoma, Hepatocellular
/ genetics
Carrier Proteins
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
Cytokines
/ genetics
Down-Regulation
Genome-Wide Association Study
/ methods
Liver Neoplasms
/ genetics
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Nude
MicroRNAs
/ genetics
Neoplasm Recurrence, Local
/ genetics
RNA, Long Noncoding
/ genetics
Signal Transduction
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
06
2018
accepted:
23
11
2018
revised:
04
10
2018
pubmed:
16
1
2019
medline:
22
5
2019
entrez:
16
1
2019
Statut:
ppublish
Résumé
Oncofetal genes are genes that express abundantly in both fetal and tumor tissues yet downregulated or undetected in adult tissues, and can be used as tumor markers for cancer diagnosis and treatment. Meanwhile, long noncoding RNAs (lncRNAs) are known to play crucial roles in the pathogenesis of hepatocellular carcinoma (HCC), including tumor growth, proliferation, metastasis, invasion, and recurrence. We performed a genome-wide screening using microarrays to detect the lncRNA expression profiles in fetal livers, adult livers, and liver cancer tissues from mice to identify oncofetal lncRNAs in HCC. From the microarray data analysis, we identified lncRNA Ptn-dt as a possible oncofetal gene. Both in vitro and in vivo experiments results confirmed that overexpression of Ptn-dt significantly promoted the proliferation of mouse HCC cells. RNA pulldown assay showed that Ptn-dt could interact with the HuR protein. Interestingly, miR-96 binds with HuR to maintain its stability as well. Overexpression of lncRNA Ptn-dt led to the downregulation of miR-96, which might be due to the interaction between Ptn-dt and HuR. Meanwhile, previous studies have reported that Ptn can promote tumor growth and vascular abnormalization via anaplastic lymphoma kinase (Alk) signaling. In our study, we found that overexpression of Ptn-dt could promote the expression of Alk through repressing miR-96 via interacting with HuR, thus enhancing the biologic function of Ptn. In summary, a new oncofetal lncRNA Ptn-dt is identified, and it can promote the proliferation of HCC cells by regulating the HuR/miR-96/Alk pathway and Ptn-Alk axis.
Identifiants
pubmed: 30643194
doi: 10.1038/s41388-018-0643-z
pii: 10.1038/s41388-018-0643-z
doi:
Substances chimiques
Biomarkers, Tumor
0
Carrier Proteins
0
Cytokines
0
MicroRNAs
0
RNA, Long Noncoding
0
pleiotrophin
134034-50-7
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3428-3445Références
Mol Carcinog. 2008 Oct;47(10):784-96
pubmed: 18381592
Gastroenterology. 2015 Feb;148(2):415-26.e18
pubmed: 25449213
Gut. 2016 Apr;65(4):683-92
pubmed: 25596181
Mol Cancer. 2015 Feb 03;14:19
pubmed: 25644401
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Prog Drug Res. 2011;67:221-38
pubmed: 21141732
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W345-9
pubmed: 17631615
J Hepatol. 2005 Jun;42(6):860-9
pubmed: 15885357
Int J Clin Exp Med. 2015 Jul 15;8(7):11683-91
pubmed: 26380005
N Engl J Med. 2013 Jun 13;368(24):2266-76
pubmed: 23758232
Eur Cytokine Netw. 2009 Dec;20(4):180-90
pubmed: 20167557
Mod Pathol. 2005 Dec;18(12):1591-8
pubmed: 15920546
Hepatology. 2014 Oct;60(4):1278-90
pubmed: 25043274
Mol Cell. 2012 Aug 24;47(4):648-55
pubmed: 22841487
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700
Curr Protein Pept Sci. 2012 Jun;13(4):372-9
pubmed: 22708488
Mol Cancer. 2012 Aug 14;11:55
pubmed: 22891627
Hepatology. 2013 Aug;58(2):739-51
pubmed: 23483581
Curr Opin Hematol. 2008 May;15(3):210-4
pubmed: 18391787
Cell. 2013 Jul 3;154(1):26-46
pubmed: 23827673
Mol Cell. 2012 Aug 24;47(4):495-6
pubmed: 22920290
PLoS One. 2012;7(10):e47876
pubmed: 23077670
PLoS Med. 2006 Jul;3(7):e232
pubmed: 16800721
Nat Rev Genet. 2016 Jan;17(1):47-62
pubmed: 26666209
Eur Urol. 2014 Jun;65(6):1140-51
pubmed: 24373479
J Biol Chem. 2002 Apr 19;277(16):14153-8
pubmed: 11809760
Hepatology. 2013 May;57(5):1882-92
pubmed: 23239537
Cell Mol Life Sci. 2001 Feb;58(2):266-77
pubmed: 11289308
Tumour Biol. 2014 May;35(5):4095-9
pubmed: 24425104
Scand J Clin Lab Invest. 1956;8(2):174
pubmed: 13351554
Int J Oncol. 2012 May;40(5):1477-82
pubmed: 22322911
Am J Pathol. 2012 May;180(5):1772-80
pubmed: 22414602
Hepatology. 2015 Sep;62(3):784-91
pubmed: 25645399
Cancer Res. 2005 Oct 1;65(19):8715-22
pubmed: 16204040
Cancer Cell. 2014 May 12;25(5):666-81
pubmed: 24768205
J Cell Biochem. 2010 Oct 15;111(3):727-34
pubmed: 20626035
Nat Biotechnol. 2011 Jul 31;29(8):742-9
pubmed: 21804560
Mol Cell Oncol. 2016 Feb 18;3(6):e1141087
pubmed: 28090572
Oncologist. 2010;15 Suppl 4:5-13
pubmed: 21115576
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Neoplasia. 2009 Feb;11(2):145-56
pubmed: 19177199
Mol Cancer. 2015 Nov 04;14:184
pubmed: 26536864
Oncogene. 2011 Apr 21;30(16):1956-62
pubmed: 21151178
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
PLoS One. 2017 Apr 17;12(4):e0175471
pubmed: 28414767
J Cell Mol Med. 2010 Dec;14(12):2697-701
pubmed: 21029369
Cancer Res. 2008 Apr 15;68(8):2587-91
pubmed: 18413726
Nucleic Acids Res. 2009 Jul;37(13):4518-31
pubmed: 19483093
Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):530-8
pubmed: 22710573
FEBS Lett. 2016 Feb;590(4):559-70
pubmed: 26801864
Nucleic Acids Res. 2013 Apr 1;41(6):e74
pubmed: 23335781